Skip to main content
. Author manuscript; available in PMC: 2022 Jun 25.
Published in final edited form as: ACS Sens. 2021 May 31;6(6):2225–2232. doi: 10.1021/acssensors.1c00124

Figure 3.

Figure 3.

In vivo biodistribution of TIRO-CyAl5.5. (A,B) Representative NIR fluorescence images of ex vivo organs harvested 30 min after intravenous administration of the indicated contrast agent. (C) Quantitative summary of fluorescence intensity of organs collected 30 min after intravenous administration of the TIRO-CyAl5.5 and free CyAl5.5, where bars represent the average (TBRs; mean ± SD) of N = 5 mice. (D) Administration of TIRO-CyAl5.5 resulted in a 2.74-fold increase in the jugular vein thrombus signal compared to free CyAl5.5. *P < 0.05.